Abbott Vascular designates Montreal Heart Institute as a Center of Excellence
Published on January 29, 2013 at 1:53 AM
The Montreal Heart Institute has just been designated as a Center of Excellence by Abbott Vascular for the percutaneous treatment of mitral valve failure with their MitraClip system. The MHI has therefore become a reference centre for this procedure for all hospitals across Canada and many other hospitals in North America.
"The Montreal Heart Institute is delighted to receive this honour and international recognition. This designation, which we received for the quality of our care and our effective, cutting-edge program, will allow us to share our expertise with the international medical community and significantly contribute to improving care for patients with mitral valve and heart failure," said Dr. Philippe L. L'Allier, director of interventional cardiology at the MHI.
The MHI joins Cedars-Sinai in Los Angeles (California) and the University of Virginia Health System (Virginia) to form a three-partner team that will train other medical centres in North America looking to start a clinical program for the percutaneous treatment of mitral valve failure with the MitraClip system.
Thanks to the exceptional clinical work of a multidisciplinary team, made up of Dr. Anita Asgar and Dr. Raoul Bonan from the Department of Interventional Cardiology, Dr. Anique Ducharme and Dr. Ars-ne Basmadjian from the Department of Echocardiography, and Dr. Jennifer Cogan and Dr. Alain Deschamps from the Department of Anesthesiology, the MHI is considered as a model to emulate.
Percutaneous implantation of the MitraClip system: an effective therapy
For some patients, the implantation of the MitraClip system is a preferable alternative to heart surgery. Until now, mitral valve failure has been treated with medication or open-heart surgery depending on the degree of severity and the primary cause. This system is a minimally invasive option for mitral regurgitation, as the interventional cardiologist makes a 3-mm incision in the groin and uses catheters to position the clip in the mitral valve without having to stop the heart. Currently, the typical population for this treatment includes inoperable or high-risk surgical patients, as the procedure poses fewer risks of complications compared to conventional surgery. Patients are generally discharged from hospital within 48 hours of surgery and do not have to undergo difficult rehabilitation.
"By allowing patients to regain independence and quality of life, this treatment reduces the number of hospital admissions and visits to emergency due to symptom reoccurrence," explained Dr. Asgar.